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Abstract
Background: Programmed Death-1 (PD-1) is an inhibitory member of the CD28 family of molecules expressed on CD8+ T
cells in response to antigenic stimulation. To better understand the role of PD-1 in antiviral immunity we examined the
expression of PD-1 on Epstein-Barr virus (EBV) epitope-specific CD8+ T cells during acute infectious mononucleosis (AIM)
and convalescence.
Methodology/Principal Findings: Using flow cytometry, we observed higher frequencies of EBV-specific CD8+ T cells and
higher intensity of PD-1 expression on EBV-specific CD8+ T cells during AIM than during convalescence. PD-1 expression
during AIM directly correlated with viral load and with the subsequent degree of CD8+ T cell contraction in convalescence.
Consistent differences in PD-1 expression were observed between CD8+ T cells with specificity for two different EBV lytic
antigen epitopes. Similar differences were observed in the degree to which PD-1 was upregulated on these epitope-specific
CD8+ T cells following peptide stimulation in vitro. EBV epitope-specific CD8+ T cell proliferative responses to peptide
stimulation were diminished during AIM regardless of PD-1 expression and were unaffected by blocking PD-1 interactions
with PD-L1. Significant variability in PD-1 expression was observed on EBV epitope-specific CD8+ T cell subsets defined by V-
beta usage.
Conclusions/Significance: These observations suggest that PD-1 expression is not only dependent on the degree of
antigen presentation, but also on undefined characteristics of the responding cell that segregate with epitope specificity
and V-beta usage.
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Introduction
Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2,
are members of the CD28 and B7 families of proteins that
participate in regulating the balance between T cell activation and
tolerance [1,2,3,4]. The interaction of PD-1 with its ligands
delivers an inhibitory secondary signal to T cells that results in the
downregulation of T cell receptor signaling and the suppression of
T cell effector functions, including T cell proliferation and
cytokine secretion. This downregulation of T cell responses is
thought to be important in the generation of central and
peripheral tolerance and in limiting immune pathology in chronic
infections. In the context of acute viral infections, PD-1 may also
play a role in the contraction of the immune response following
acute infection [5].
High levels of PD-1 expression on virus-specific CD8+ T cells
during chronic human (human immunodeficiency virus [HIV],
hepatitis B virus [HBV]), monkey (simian immunodeficiency virus
[SIV]), and murine (lymphocytic choriomeningitis virus [LCMV])
infections have been associated with T cell dysfunction and failure
to control viral replication [6,7,8,9,10,11,12,13,14,15,16,17,18,
19,20]. However, Kasprowicz and colleagues have recently
reported high levels of PD-1 expression on peripheral blood
hepatitis C virus (HCV)-specific CD8+ T cells of infected
individuals who clear infection, raising the question of whether
PD-1 expression alone is sufficient to confer T cell dysfunction
[10]. In non-persistent viral infections, PD-1 expression is
downregulated with the resolution of acute infection and viral
clearance. Salisch and colleagues have recently reported that the
upregulation and maintenance of high PD-1 expression levels on
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antigen-specific CD8+ T cells is dependent on continued
activation through the T cell receptor in lentiviral infections [16].
Epstein Barr virus (EBV) infects over 95% of the world’s
population but is only rarely associated with disease despite
persistent viral replication in chronically infected individuals [21].
Primary EBV infection in adolescence and young adulthood is
often symptomatic, with a syndrome characterized by fever,
malaise, pharyngitis and lymphadenopathy (acute infectious
mononucleosis, AIM; reviewed in [22]). Vigorous EBV-specific
CD4+ and CD8+ T cell responses are expanded early in AIM
[23,24,25]; several lines of evidence suggest that these cellular
immune responses are important for limiting primary EBV
infection and controlling chronic infection such that diseases
associated with EBV are relatively rare.
Human EBV infection has served as a useful model in efforts to
characterize the lineage relationship between effector and memory
responses and the factors that influence evolution of antigen-
specific CD8+ T cell responses into the memory CD8+ T cell
repertoire. Current models of EBV viral immunology link the
phenotypes of EBV-specific CD8+ T cells detected in the
circulation with the levels of viral antigen expression and/or the
qualitative differences in their presentation [24,26,27,28,29,30].
Several investigators have reported high levels of PD-1 expression
on EBV-specific CD8+ T cells during chronic infection [8,13].
Sauce and colleagues have reported that EBV-specific CD8+ T
cells culled from the circulation during convalescence transiently
express PD-1 at high levels concurrent with gradually increasing
IL-7R (CD127) expression [31]. We studied PD-1 expression
levels on EBV-specific CD8+ T cells during AIM, convalescence
and chronic infection to better define its relationship with viral
replication, the contraction of the immune response, and CD8+ T
cell functional properties.
Methods
Ethics Statement
The Institutional Review Board of the University of Massachu-
setts Medical School approved these studies, and all participants
provided written informed consent.
Study Population
Students at the University of Massachusetts, Amherst campus
were invited to participate in this study when they presented to the
infirmary with symptoms consistent with acute infectious mono-
nucleosis (AIM) and a positive monospot (heterophile antibody)
assay. All were confirmed to have acute EBV infection by the
detection of IgM antibodies to the EBV Viral Capsid Antigen.
Blood samples were collected at baseline, weekly for six weeks,
followed by long-term follow-up at six months and one year.
Individuals with EBV-specific CD8+ T cells detected using HLA-
A*0201 based, peptide-MHC Class I (pMHCI) tetramers
(described below) were selected for more detailed studies.
Flow Cytometry
Whole blood samples were screened for EBV-specific CD8+ T
cells that reacted with APC-conjugated pMHCI tetramers in-
cluding HLA-A*0201 based reagents: A2-BMLF-1 (epitope: GLC-
TLVAML), A2-BRLF-1 (epitope: YVLDHLIVV), A2-EBNA-3c
(epitope: LLDFVRFMGV), and the HLA-B*0702-based reagent:
B7-EBNA-3a (epitope: RPPIFIRRL). All pMHCI tetramer com-
plexes were made in the Tetramer Core facility at UMMS as
previously described [32].
PBMC samples were studied using a PE-conjugated antibody
specific for PD-1 (Medarex). Antibodies from BD-Biosciences (San
Jose, CA) were used to detect: CD27 (Alexa700), CD28 (PE-Cy7),
CD127 (FITC or PE), HLA-DR (FITC or PerCP). A panel of
FITC-conjugated antibodies specific for different V-beta subsets
(Immunotech/Beckman Coulter) was used in a four-color assay
that also included CD8 (PerCP), PD-1 (Medarex; PE), and
Tetramer (APC). For multi-parameter flow assays, a ‘‘dump
channel’’ of cells positive for CD14 and CD19 (APC-Cy7) was
used to improve specificity, and live/dead blue reagent (Invitro-
gen) was used to exclude dead cells. Unstained and ‘‘fluorescence
minus one’’ samples were included as controls in all experiments to
optimize specificity during analyses.
Assays involving#four fluorochromes utilized FACScan or
FACSCalibur instruments (BD Biosciences), with CellQuest
software (BD Biosciences). For experiments involving.four
fluorochromes, we used a LSRII instrument (BD Biosciences).
Multiparameter flow cytometry data were analyzed using FlowJo
software (Treestar, Ashland OR) and programs generously
provided by Mario Roederer (PESTLE and SPICE version 4.2).
A complete blood count with differential was obtained at each
study visit. The absolute lymphocyte count was calculated by
multiplying the white blood cell count (#/ml) by the lymphocyte
percentage. The absolute CD8+ T cell count was calculated by
multiplying the absolute lymphocyte count by the CD8+
percentage. The absolute counts of virus-specific CD8+ T cells
were calculated by multiplying the absolute CD8+ T cell count by
the percentages of epitope-specific CD8+ T cells.
The PD-1 median fluorescence index (MFI) values on virus-
specific CD8+ T cells were expressed as normalized values: the
ratio between the PD-1 median fluorescence intensity and the
cutoff between PD-1 positive and negative CD8+ T cells.
Peptide Stimulation
Cryopreserved PBMC were thawed into RPMI 1640, contain-
ing 10% heat inactivated human AB sera, 2mM L-glutamine,
100 U/ml gentamicin (R10 medium; all materials from Gibco),
with 2 mg/ml DNase (Sigma) and pelleted. Cells were re-
suspended at 10 million/ml, incubated with CFSE (Invitrogen)
at a final concentration of 0.5mM for 10 minutes at 37uC, 5%
CO2 and 95% humidity. Cells were cultured at 1.5 to 3 million
cells/ml in R10 medium containing co-stimulatory antibodies,
CD49d and CD28 (final concentration of 1ug/ml; both from BD
Pharmingen), the EBV peptide of interest (final concentration
10 mg/ml), no peptide, or Candida antigen. Cells in each assay
condition were incubated at 150,000 to 300,000 cells per well in
96-well microtiter plates, in replicates of 10. After 6 days, they
were harvested, pooled, treated with 20 mM EDTA for 15 min-
utes, and washed with 1% BSA/PBS in preparation for antibody
staining. Cells were then stained with relevant APC-conjugated
pMHCI tetramers, PD-1 (PE) (Medarex), and CD8 (PerCP; BD
Biosciences). Anti-PD-L1 antibody (EBioscience, # 16-5983),
when included in blocking assays, was used at a concentration of
25 mg/ml and was added simultaneously with peptide.
EBV DNA Quantitation in B Cells
B-cells were purified from whole blood using the RosetteSep
human B-cell enrichment cocktail and manufacturer’s protocol
(StemCell Technologies, Vancouver BC, Canada). Cellular DNA
was extracted using QIAGEN DNeasy mini spin columns
(Valencia, CA). The Roche LightCycler EBV Quantitation Kit
was used to quantify EBV DNA copy number. Cell counts in each
sample were determined using a previously described PCR assay
to quantify the copy number of the gene encoding CCR5 (two
copies per diploid cell) [25].
PD-1 on EBV-Specific T Cells
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Statistics
GraphPad Prism version 5.0 for Mac OSX (GraphPad
Software, La Jolla, CA) was used for all statistical analyses. The
Wilcoxon Signed Rank test was used for paired comparisons. The
Spearman rank test was used for analyses of correlations. To
determine if V-beta subsets had significantly different expression of
PD-1 than the overall Tetramer positive subpopulation we used
the range defined by the mean +/2 3*SD of PD-1 expression on
Tetramer positive cells.
Results
PD-1 Expression is Upregulated on EBV-specific CD8+ T
Cells in AIM
CD8+ T cells undergo marked expansion during AIM,
primarily due to the expansion of EBV epitope-specific CD8+ T
cells (reviewed in [33]). Lytic epitope-specific CD8+ T cell
responses are most highly expanded during acute EBV infection;
in some individuals, CD8+ T cells specific for a single lytic epitope
may represent more than 25% of the total circulating CD8+ T
cells [24,30,33]. Latent epitope-specific CD8+ T cells are less
highly expanded during AIM and convalescence.
We measured HLA A*0201-restricted, EBV-specific epitope-
specific CD8+ T cells in peripheral blood samples obtained from
13 individuals during AIM (within the first two weeks after
presentation with symptoms) and convalescence (6 to 12 months
after presentation with symptoms; Figure 1A). CD8+ T cells were
expanded in AIM and contracted (3.7-fold decrease in mean
value) in convalescence. CD8+ T cells specific for an HLA-A*0201
restricted epitope in the immediate early lytic protein, BRLF-1,
(YVLDHLIVV; hereafter abbreviated A2-BRLF-1 CD8+ T cells)
were most highly expanded during AIM, and underwent the
greatest degree of contraction (48.7-fold decrease in mean value) in
convalescence. CD8+ T cells specific for an HLA A2-restricted
epitope in the early lytic protein, BMLF-1, (GLCTLVAML;
hereafter abbreviated A2-BMLF-1 CD8+ T cells) were also highly
expanded during AIM, but underwent a smaller contraction (12.2-
fold decrease in mean value) in convalescence. CD8+ T cells
specific for an HLA A2-restricted epitope in the latent antigen,
EBNA-3c, (LLDFVRFMGV; hereafter abbreviated A2-EBNA-3c
CD8+T cells) were even less highly expanded (detected in only 5 of
13 individuals at each time point) and underwent a 17.6-fold
decrease in mean value from AIM to convalescence. These
changes in circulating EBV epitope-specific CD8+ T cell numbers
coincided with a 17.5-fold decrease in mean peripheral blood EBV
DNA copy number over the same time period (Figure 1B). They
are consistent with previous reports showing a larger decline in
A2-BRLF-1 CD8+ T cell frequencies than either A2-BMLF-1 or
A2-EBNA-3c CD8+ T cells [21,29].
We next examined PD-1 expression on EBV-specific CD8+ T
cells in these individuals from AIM through convalescence. During
AIM, 55.2 to 96.3% (median 76.3%) of A2-BMLF1-specific CD8+
T cells expressed PD-1 (Figure 2A). The frequencies of A2-BMLF1-
specific CD8+ T cells expressing PD-1 remained high in
convalescence (36.6 to 85.9%; median 71.5%), but were signifi-
cantly lower than during AIM (Wilcoxon signed rank test, p,0.05).
Similarly, high frequencies of PD-1+ A2-BRLF1-specific CD8+ T
cells were detected during AIM (28.4 to 88.6%, median 61.0%), and
decreased significantly in convalescence (10.3 to 80.0%, median
35.1%; Wilcoxon signed rank test, p,0.05). Similar trends were
observed for two additional EBV epitope-specific responses (A2-
EBNA-3c and B7-EBNA-3a CD8+ T cells, Figure 2A).
Figure 1. EBV-specific CD8+ T cells and viral load during AIM and convalescence. A. Absolute values (cells per ml) of CD8+ T cells, and
three different EBV-specific subsets (lytic and latent antigen specific) measured in samples from individuals during AIM (within the first two weeks
after presentation with symptoms) and convalescence (CONV; 6–12 months after presentation with symptoms). A2-BMLF-1 CD8+ T cells: specific for
the HLA-A*0201 restricted epitope of BMLF-1, GLCTLVAML; A2-BRLF-1 CD8+ T cells: specific for the HLA-A*0201 restricted epitope of BRLF-1,
YVLDHLIVV; A2-EBNA-3c CD8+ T cells: specific for the HLA-A*0201 restricted epitope of EBNA-3c, LLDFVRFMGV. When no EBV-specific CD8+ T cells
were detected with these reagents, a value of 100 cells per milliliter was assigned (less than half the lowest detected value). B. Viral load (EBV copies
per million B cells) during AIM and convalescence. Lines define paired results for each individual. All paired comparisons indicated by brackets differ
significantly by the Wilcoxon signed rank test; * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0012926.g001
PD-1 on EBV-Specific T Cells
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Higher intensity of PD-1 expression was also observed on EBV
epitope-specific CD8+ T cells during AIM compared with
convalescence (Figure 2B). The PD-1 median fluorescence index
(MFI) values on A2-BMLF-1 (mean= 3.9) and A2-BRLF-1
(mean=2.0) CD8+ T cells during AIM were significantly higher
than during convalescence (mean= 2.1 for A2-BMLF-1 and 0.9
for A2-BRLF-1 CD8+ T cells); a similar trend was observed for
A2-EBNA-3c CD8+ T cells.
Because high levels of expression of PD-1 are associated with
loss of function or ‘‘exhaustion’’ [2], we also evaluated cell
populations that were PD-1high, PD-1dim, or PD-1negative. Using a
gating strategy based on a consistent contour ‘‘shoulder’’ observed
in CD8+ T cell population plots of PD-1 against FSC or SSC
(Figure 3A), we were able to analyze our data in a manner
consistent with previous reports [14]. In total, CD8+ T cells
expressed PD-1 at higher intensities during AIM (median 12.5;
range 1.8 to 33.2) compared with convalescence (median 5.3;
range 1.9 to 8.6; Figure 3B). These convalescent values are similar
to those reported for HIV-1 infected individuals on effective
antiretroviral therapy [14].
Among EBV-specific CD8+ T cells, only A2-BMLF-1 and A2-
BRLF-1 CD8+ T cells were present in frequencies sufficient for
analysis at this level of detail. High-level expression of PD-1 (PD-
1high) was detected on a significantly greater percentage of EBV-
specific CD8+ T cells during AIM than during convalescence
(Figure 3C). For example, the frequencies of A2-BMLF-1 CD8+ T
cells that were PD-1high during AIM ranged from 11.3 to 46.5%
(median 26.2%), and during convalescence ranged from 4.4 to
20.6% (median 8.4%). Thus the percentages of EBV epitope-
specific CD8+ T cells with high-level PD-1 expression changed
significantly between AIM and convalescence (Wilcoxon signed
rank test, p,0.001 and 0.027 for A2-BMLF-1 and A2-BRLF-1
CD8+ T cells, respectively).
In summary, we have demonstrated higher frequencies of PD-
1+ EBV-specific CD8+ T cells, as well as higher intensity of PD-1
expression during AIM compared with convalescence. These
findings are consistent with the hypothesis that PD-1 expression is
largely driven by antigenic stimulation. The differences in intensity
of PD-1 expression (MFI and high level expression) are likely to be
most biologically meaningful given prior studies demonstrating
increased sensitivity to apoptosis and reduced proliferative
capacity of CD8+ T cells with high intensity PD-1 staining
[14,34].
Expression of PD-1 on CD8+ T Cells During AIM
Correlates with Peripheral Blood EBV Load
We noted substantial variability in the frequency and intensity
of PD-1 staining on CD8+ T cells between individual patients. In
chronic lentiviral infections, the frequency and intensity of PD-1
expression on virus-specific CD8+ T cells directly correlates with
plasma viral RNA copy number (a direct measure of viral
replication) [16].
EBV replication is thought to occur primarily in oropharyngeal
B cell blasts and epithelial cells; direct measurement of EBV
replication at these sites is difficult. Peripheral blood EBV load
(EBV DNA copy numbers in latently-infected memory B-cells) is
easily measurable. Hadinoto et al [35] have demonstrated that
high levels of EBV lytic replication during AIM results in very high
levels of circulating latently-infected memory B cells; a marked
reduction in peripheral blood EBV load is observed during
convalescence as EBV-specific CD8+ T cells limit rounds of lytic
viral replication and resultant seeding of the peripheral blood
memory B cell pool.
In samples obtained during AIM (a period of active EBV
replication and seeding of the peripheral blood memory B cell
pool), there was a significant positive correlation between the viral
load (EBV DNA copies per million B cells) and the MFI of CD8+
T cells expressing PD-1 (Figure 4A, left panel; Spearman
correlation: r = 0. 698; p = 0.008). The CD8+ T cell PD-1
percentage was also significantly correlated with EBV load (data
not shown; Spearman correlation: r = 0.747; p = 0.003). PD-1
expression on both A2-BMLF-1 and A2-BRLF-1 CD8+ T cells
showed a weaker positive correlation with viral load during AIM,
reaching statistical significance only for A2-BRLF-1 CD8+ T cells
(Figure 4A, right panel; A2-BRLF-1 PD-1 MFI and viral load;
Spearman correlation: r = 0.560; p = 0.046). PD-1 expression on
CD8+ T cells did not correlate with viral load in samples obtained
during convalescence.
Figure 2. PD-1 expression on EBV-specific CD8+ T cells at AIM
and convalescence. A. The percentages of EBV-specific CD8+ T cells
that expressed PD-1 are shown. Two lytic (A2-BMLF-1 and A2-BRLF-1)
and two latent (A2-EBNA-3c and B7-EBNA-3a CD8+ T cells) antigen
specific CD8+ T cell subsets are shown. Lines define paired results for
each individual. B. The median fluorescence index (MFI) of PD-1
expression for these EBV-specific CD8+ T cells is shown. All assays were
performed with the PD-1 antibody conjugated to PE. The MFI was
normalized as described in methods. Lines define paired results for each
individual. All paired comparisons indicated by brackets differ
significantly by the Wilcoxon signed rank test; * p,0.05, ** p,0.01,
*** p,0.001.
doi:10.1371/journal.pone.0012926.g002
PD-1 on EBV-Specific T Cells
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12926
Expression of PD-1 on CD8+ T Cells During AIM
Correlates with Contraction in Convalescence
It has been reported that EBV-specific responses that are
differentially ‘‘culled’’ may have different levels of PD-1 expres-
sion; higher PD-1 expression was detected on certain epitope-
specific CD8+ T cells at time points just prior to the disappearance
of these CD8+ T cells from the peripheral circulation [31]. In
animal models of uncontrolled infection, PD-1 expression
decreased on epitope-specific CD8+ T cells as they decreased in
frequency in the context of emerging viral escape mutations
[16,34,36]. We, therefore, examined the relationship between PD-
1 expression on EBV epitope-specific CD8+ T cells during AIM
and the degree to which these cell populations contracted between
AIM and convalescence.
We observed a significant positive correlation between the
intensity of PD-1 expression and the fold-change (decrease) in the
absolute number of circulating CD8+ T cells between AIM and
convalescence (Figure 4B, left panel; MFI vs. fold-change;
Spearman r= 0.955; p,0.0001). This relationship was also
observed for the percentage of PD-1 positive CD8+ T cells;
Spearman r= 0.891; p = 0.0005; data not shown). The intensity of
PD-1 expression on both A2-BMLF-1 and A2-BRLF-1 CD8+ T
cells also showed a significant positive correlation with the degree
of contraction between AIM and convalescence (Figure 4B, right
panel; Spearman correlations and p-values, respectively: r = 0.646,
p = 0.037 and r = 0.764, p = 0.009). This relationship was also
observed for the percentage of PD-1 positive cells in each of these
subsets, but reached significance only for the A2-BRLF-1 CD8+ T
cells (data not shown; Spearman correlation: r = 0.665; p = 0.031).
These data are consistent with antigen driven expansion and
upregulation of PD-1 on virus-specific CD8+ T cells during AIM.
However, PD-1 expression on A2-BRLF-1 CD8+ T cells was
more strongly associated with viral load and the degree of
contraction than was PD-1 expression on A2-BMLF-1 CD8+ T
cells.
Consistent Differences in PD-1 Expression are Observed
on EBV Epitope-specific CD8+ T Cells
In our analyses, we consistently observed lower frequencies and
intensities of PD-1 expression on A2-BRLF-1 CD8+ T cells
compared with A2-BMLF-1 CD8+ T cells. A representative
example of this is shown in Figure 5. In this example, 94% of A2-
BMLF-1 and 87% of A2-BRLF-1CD8+ T cells during AIM
expressed PD-1. At this time point, the MFI of PD-1 expression for
A2-BMLF-1 and A2-BRLF-1 were 3,236 and 2,491, respectively.
At week 52 (convalescence), 80% of A2-BMLF-1 and 65% of A2-
Figure 3. High level PD-1 expression on CD8+ T cells during AIM and convalescence. A. Representative CD8+ T cell plots of a sample
obtained during AIM demonstrating the gating strategy to define PD-1 high, dim and negative populations. B. Percentages of PD-1 high, dim, or
negative CD8+ T cells in AIM and convalescence. C. Percentages of PD-1 high, dim, or negative A2-BMLF-1 and A2-BRLF-1 CD8+ T cells in AIM and
convalescence. Lines define paired results for each individual. Brackets indicate that differences between selected comparisons are significant
(Wilcoxon signed rank test; *p,0.05, ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0012926.g003
PD-1 on EBV-Specific T Cells
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BRLF-1 CD8+ T cells expressed PD-1, and PD-1 MFI were 1,585
and 985, respectively. Overall, the percentages of A2-BMLF-1
CD8+ T cells that expressed PD-1 were significantly greater than
the percentages of A2-BRLF-1 CD8+ T cells, both during AIM
and convalescence (Figure 2A; Wilcoxon signed rank test, p,0.01
for both comparisons). In addition, we observed higher intensity
(MFI) of PD-1 staining in A2-BMLF-1 CD8+ T cells compared
with A2-BRLF-1 CD8+ T cells (Figure 2B; Wilcoxon signed rank
test, p,0.01 for both comparisons). Finally, significantly higher
frequencies of A2-BMLF-1 CD8+ T cells expressed PD-1 at high
levels (PD-1high) during AIM compared with A2-BRLF-1 CD8+ T
cells (Figure 3C; Wilcoxon signed rank test, p,0.001). During
both AIM and convalescence, we observed a lower frequency of
PD-1negative A2-BMLF-1 CD8+ T cells compared with A2-BRLF-
1 CD8+ T cells (Figure 3C; Wilcoxon signed rank test, p,0.001
for both comparisons).
Again, this analysis included measures of the intensity of PD-1
expression (MFI and PD-1high percentage) on virus-specific CD8+
T cells because they are considered to be more biologically
meaningful. Given the higher degree of contraction of A2-BRLF-1
CD8+ T cells (48.7-fold decrease in mean values) following AIM,
and prior reports that PD-1 expression is significantly correlated
with contraction, it was surprising to find that the intensity of PD-1
expression was lower than that of A2-BMLF-1 CD8+ T cells both
in AIM and convalescence. Data presented in Figure 4B (right
panel) underscores the observation of consistently higher levels of
PD-1 expression on A2-BMLF-1 CD8+ T cells compared with A2-
BRLF-1 CD8+ T cells. It is also evident that there may be a
significant correlation between PD-1 expression and degree of
contraction for a particular subset of virus-specific CD8+ T cells,
however this relationship may differ substantially for another
subset.
We (Catalina, et al 2001), and others have previously shown
that EBV latent epitope-specific CD8+ T cells undergo lower
levels of expansion and contraction than lytic epitope-specific
CD8+ T cells [24,29]. A robust comparison of PD-1 expression on
Figure 4. PD-1 expression on CD8+ T cells during AIM: correlations with viral load and contraction at convalescence. A. Left panel:
Viral load (log transformed) and the corresponding PD-1 MFI of CD8+ T cells are plotted (Spearman r = 0.698; p = 0.008). Right panel: Viral load (log
transformed) and the corresponding PD-1 MFI of A2-BMLF-1 (solid squares, dotted line) and A2-BRLF-1 cells (open circles, solid line) are plotted
(Spearman r = 0.170; p = 0.578 and r = 0.560; p = 0.046, respectively). B. Left panel: PD-1 MFI of CD8+ T cells during AIM and the corresponding fold-
change in CD8+ T cells (log-transformed) are plotted (Spearman r = 0.955; p,0.0001). The fold-change in CD8+ T cells is the ratio of the cell #/ml
during AIM over the cell #/ml during convalescence. Right panel: PD-1 MFI of A2-BMLF-1 (solid squares, dotted line) and A2-BRLF-1 cells (open
circles, solid line) during AIM and the corresponding fold-change in each of these subsets (log-transformed) are plotted (Spearman r = 0.646;
p = 0.037, and r = 0.764; p = 0.009, respectively). Lines of best fit are shown for each combination of variables.
doi:10.1371/journal.pone.0012926.g004
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lytic and latent antigen-specific CD8+ T cells was not feasible due
to the markedly lower frequencies of detectable latent antigen-
specific CD8+ T cells. However, in samples where latent epitope
specific CD8+ T cells were also detected in sufficient numbers
(e.g., A2-EBNA-3c and B7-EBNA-3a CD8+ T cells; Figure 2), PD-
1 expression levels generally exceeded those measured on A2-
BRLF1 CD8+ T cells. These data suggest that PD-1 expression
may not be the sole factor influencing contraction of a CD8+ T
cell response in convalescence.
Differences in PD-1 Expression on EBV-specific CD8+ T
Cells are not Related to Measurable Differences in
Differentiation State or Activation
PD-1 expression on virus-specific CD8+ T cells has been
regarded as a sensitive marker of antigenic stimulation [16]. The
differences in PD-1 expression on A2-BMLF-1 and A2-BRLF-1
CD8+ T cells could be consistent with quantitative or qualitative
differences in antigen stimulation. If this were the case, these cells
would be expected to display differences in other markers of
differentiation or activation. We studied a subset of our population
(n = 5) to determine whether there were any identifiable
differences in differentiation between A2-BMLF-1 and A2-
BRLF-1 CD8+ T cells. We found that the major differentiation
states defined by CD27, CD28 and CD127 were similarly
represented in these two EBV-specific CD8+ T cell subsets (data
not shown). The highest PD-1 levels were observed on effector
memory cells in early/intermediate stages of differentiation
(CD27+28+1272) both in AIM and convalescence.
High frequencies (92 to 100%) of EBV epitope-specific CD8+ T
cells expressed HLA-DR during AIM. Fewer A2-BMLF-1 (16 to
48%, median 28%) and A2-BRLF-1 (6 to 41%; median 22%)
CD8+ T cells expressed HLA-DR during convalescence. HLA-
DR expression did not correlate with PD-1 expression during AIM
or convalescence (data not shown).
PD-1 Expression on EBV-specific CD8+ T Cells Does Not
Correlate with CD127 Expression
Previous reports have related CD127 (IL-7R) expression with
the expansion and contraction of EBV-specific CD8+ T cells in
AIM and convalescence [26]. Sauce et al [31] have recently
reported a gradual increase in CD127, and a transient high
intensity upregulation of PD-1 expression on EBV epitope-specific
CD8+ T cells prior to their disappearance from the circulation.
Our analysis did not detect evidence of higher PD-1 expression on
Figure 5. Differential PD-1 expression on A2-BMLF-1 and A2-BRLF-1 CD8+ T cells at AIM and convalescence. PD-1 expression on A2-
BMLF-1 and A2-BRLF-1 CD8+ T cells during AIM (upper panels) and convalescence (lower panels). Representative dot plots demonstrate differences in
PD-1 percent positivity, and histograms showing differences in distribution and PD-1 MFI of these EBV-specific CD8+ T cells. Histograms overlay the
two subsets on a background of the total CD8+ T cell population.
doi:10.1371/journal.pone.0012926.g005
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a more rapidly contracting population of EBV-specific CD8+ T
cells (the A2-BRLF-1 CD8+ T cells), so we examined CD127
expression in greater detail.
CD127 expression was examined from AIM through convales-
cence in seven individuals. The percentages of A2-BMLF-1 and
A2-BRLF-1 CD8+ T cells that expressed CD127 ranged from 0.7
to 18.9% (median 5.8%) and 0.4 to 31.6% (median 6.1%) during
AIM, respectively. The frequencies of CD127+ virus-specific
CD8+ T cells trended upward in convalescence but reached
significance only for A2-BRLF-1 CD8+ T cells (Figure 6A;
Wilcoxon signed rank test, p = 0.047).
Within PD-1high subpopulations, EBV-specific CD8+ T cells
expressed CD127 at low frequencies that did not differ from the
total CD8+ T cell population either during AIM or convalescence
(Figure 6B). Within PD-1negative subpopulations, EBV-specific
CD8+ T cells expressed CD127 at low frequencies that did not
differ from PD-1high subpopulations at either time point.
Reduced Proliferative Capacity of EBV Epitope-specific
CD8+ T Cells in AIM Regardless of PD-1 Expression Levels
High intensity expression of PD-1 on CD8+ T cells has
correlated most consistently with poor proliferation and sensitivity
to apoptosis [34]. In samples from individuals with AIM, we
consistently observed dramatic EBV epitope-specific CD8+ cell
loss in tissue culture when compared with samples obtained in
convalescence. This cell loss occurred spontaneously (even without
stimulation) and was associated with a profound lack of response to
EBV peptide stimulation (Figure 7A, top panels). In AIM, neither
A2-BMLF-1 nor A2 BRLF-1 CD8+ cells proliferated in response
to peptide stimulation. The degree to which these EBV epitope-
specific cells were lost over the course of a 6-day assay was greater
than would be predicted from the percentage of cells expressing
high PD-1 levels. In the representative AIM example shown in
Figure 7A, the frequencies of A2-BMLF-1 and A2-BRLF-1 CD8+
T cells expressing high levels of PD-1 at baseline prior to
stimulation were 37.8% and 19.8%, respectively. For each assay
condition it was estimated that 217,500 A2-BMLF-1 CD8+ T cells
and 322,500 A2-BRLF-1 CD8+ T cells were present initially.
After 6 days with peptide stimulation, there were fewer than 200
cells that responded specifically to the BMLF-1 or the BRLF-1
peptide (by CFSE dilution). These decreases were also document-
ed by similar reductions in tetramer positive cells (data not shown).
From these data, it was apparent that both PD-1 positive and
negative virus-specific cells failed to proliferate. The lack of
responsiveness to stimulation and cell loss in AIM were virus
specific; proliferative responses to Candida antigen were preserved
in AIM and convalescence (data not shown).
In samples obtained during convalescence, A2-BMLF-1 and A2-
BRLF-1 CD8+ T cells proliferated to a similar extent with peptide
stimulation. The median fold-change in frequency of peptide
responsive cells relative to baseline frequency of tetramer positive
cells for A2-BMLF-1 CD8+ T cells was 2.1 (range 0.4 to 23.3), and
for A2-BRLF-1 CD8+ T cells was 4.3 (range 1.2 to 23.8). There was
no evidence of impaired proliferation with the A2-BMLF-1 peptide
compared to the A2-BRLF-1 peptide; indeed in some assays, A2-
BMLF-1 proliferation was more pronounced despite higher
expression of PD-1 on these cells (Figure 7A, chronic infection).
The addition of antibody that blocked PD-1/PD-L1 interac-
tions to assays on samples from AIM patients did not reverse the
observed defects in proliferation. In contrast, samples from
convalescent individuals demonstrated enhanced proliferative
responses to BMLF-1 and BRLF-1 peptides (1.3–2.1-fold, mean
1.8-fold) in the presence of antibody to block PD-1/PD-L1
interactions (data not shown).
PD-1 expression was upregulated on cells responding to peptide
stimulation (Figure 7A). In a series of assays, the PD-1 MFI of
Figure 6. Analysis of CD127 and PD-1 expression onCD8+ T cells. A. Percentages of A2-BMLF-1, A2-BRLF-1, and total CD8+ T cells that are CD127+
in AIM and convalescence (mean and SEM).B. Percentages of A2-BMLF-1, A2-BRLF-1, and total CD8+ T cells subsets that are PD-1 high or PD-1 negative that
are also CD127+ (in AIM and convalescence). Brackets indicate paired comparisons that differ significantly, Wilcoxon signed rank test, *p,0.05.
doi:10.1371/journal.pone.0012926.g006
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peptide stimulated CD8+ T cells ranged from approximately 2 to
10 times that of medium control. Interestingly, the pattern of PD-1
expression following stimulation was similar to that observed ex
vivo; CD8+ T cells responding to A2-BRLF-1 peptide had lower
intensity PD-1 expression than those responding to the A2-BMLF-
1 peptide (Figure 7B).
PD-1 Expression on V-beta Subsets of EBV Lytic Antigen
Epitope Specific CD8+ T Cells Varies Significantly
The observed differences in PD-1 expression on A2-BMLF-1
and A2-BRLF-1 CD8+ T cells raised the possibility that PD-1
expression may be influenced significantly by factors other than
antigen presentation. We hypothesized that differences in the
effectiveness of TCR engagement and signaling would also
influence PD-1 expression. If the main determinant of PD-1
expression level were antigenic stimulation, then different
clonotypes within A2-BMLF-1 or A2-BRLF-1 populations would
be expected to have similar levels of PD-1 expression (assuming
that all subsets of cells with a given epitope specificity are
presented with a similar level of antigen in a similar context and
time frame). If, however, significant variability in PD-1 expression
were to exist among clonotypes with identical epitope specificity,
then factors specific to particular clonotypes of responding cells
would be implicated as determinants in addition to the level of
antigen presentation.
To address this question, we examined PD-1 expression on V-
beta subsets of A2-BMLF-1 and A2-BRLF-1 CD8+ T cells from
three individuals with AIM. Subsets with sufficient numbers of
analyzable events (mean 129; range 24 to 702) were selected.
These V-beta subsets were compared with the total tetramer
positive population (representative gating and PD-1 expression
shown in Figure 8A). Multiple measurements of PD-1 expression
on Tetramer positive cells in a given assay enabled calculation of
Figure 7. Proliferation and PD-1 expression on CD8+ T cells responding to peptide stimulation. A. Three representative examples of
proliferation upon stimulation with HLA-A*0201-restricted BMLF-1 and BRLF-1 peptides. Upper and middle rows: PBMC from an individual at
presentation with AIM and in convalescence; lower row: PBMC from an individual with chronic infection. Left panels (baseline prior to peptide
stimulation) show PD-1 expression of the indicated tetramer positive cells (A2 BMLF-1 black line; A2 BRLF-1 grey line) superimposed on that of CD8+
T cells (grey solid). Middle panels show CD8+ T cells that proliferate (CFSE dilution) in response to the indicated peptides (A2 BMLF-1 black line; A2
BRLF-1 grey line) superimposed on unstimulated controls (grey solid). Right panels show the upregulation of PD-1 on CD8+ T cells responding to the
indicated peptides superimposed on unstimulated CD8+ T cells. Marked regions on histograms depicting PD-1 expression indicate high levels of
expression with corresponding percentages of A2 BMLF-1 and A2-BRLF-1 CD8+ T cells. Numbers in text boxes are the percentages of CD8+ T cells
that are positive for each tetramer at baseline (left panels), or responding to peptide post-stimulation (CFSE low; middle panels). B. Upregulation of
PD-1 on cells responding to stimulation with A2-BMLF-1 and A2-BRLF-1 peptides. Results shown are a mixture of chronic and convalescent samples in
three separate assays. To demonstrate the extent of PD-1 upregulation observed, PD-1 MFI is expressed as a ratio of the MFI of cells that responded
to peptide, relative to the MFI in control assays without peptide. Median PD-1 MFI ratio values for A2-BMLF-1 and A2-BRLF-1 were 8.1 and 2.8,
respectively (Wilcoxon signed rank test; p = 0.06). Solid and open symbols demonstrate paired values for A2-BMLF-1 and A2-BRLF-1 for each sample.
doi:10.1371/journal.pone.0012926.g007
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mean and standard deviation (SD). For all three individuals, we
observed clear examples of V-beta subpopulations that had PD-1
expression significantly higher or lower than the range defined by
mean +/2 3*SD (representative data shown in Figure 8B). At
early visits, these differences did not appear to predict loss or
enrichment of particular V-beta subsets at subsequent visits
(Figure 8B). For example, Vb 21.3 had high PD-1 expression,
yet persisted at a relatively high percentage (21.1%) in convales-
cence. Nor did PD-1 expression correlate with the frequency of a
particular V-beta subset; high PD-1 expression was found on
subsets that were present at persistently low or high frequencies
(e.g. Vb 22 frequencies ranged between 2.7 and 3.1% and Vb 21.3
frequencies ranged between 33.1 and 22.1% despite both
expressing high frequencies and intensities of PD-1).
Discussion
Consistent with prior reports, our analyses suggest that PD-1
expression is driven in large part, but not solely, by viral antigen
expression. Moreover, PD-1 expression alone does not reflect the
functional capacity of CD8+ T cells. Factors other than PD-1
appear to participate in: 1) modulating EBV-specific CD8+ T cell
proliferative capacity during both AIM and convalescence, 2)
determining states of differentiation and activation, 3) and the
degree of contraction of EBV-specific CD8+ T cells in
convalescence. These observations serve to refine and extend
our understanding of the complex network of factors that govern
immune responses and tolerance. To our knowledge, this is the
first demonstration that PD-1 expression on virus-specific CD8+ T
cells is influenced significantly by factors intrinsic to the
responding cell that segregate with epitope specificity and V-beta
usage. While these factors have yet to be defined, these
observations would be consistent with variable TCR binding
and signaling characteristics that may play a significant role in
shaping effective immune responses. Price et al have shown that
immunodominant clonotypes of EBV and CMV specific CD8+ T
cells tend to have greater avidity for their cognate antigen [37].
While we have not shown a relationship between PD-1 and the
Figure 8. PD-1 expression on V-beta subsets of A2-BRLF-1 CD8+ T cells in AIM. A. Representative data from one individual. Left panels show
dot plots of regions defining A2 BRLF-1 CD8+ T cells, and Vb 1 and Vb 17 subsets. Right panel is a histogram showing the PD-1 expression of all A2 BRLF-
1 CD8+ T cells (grey line), and the A2 BRLF-1 Vb 1 (red line), and A2 BRLF-1 Vb 17 (blue line) subsets superimposed on the PD-1 expression of the total
CD8+ T cell population (grey solid). B. PD-1 expression on all V-beta subsets of A2 BRLF-1 CD8+ T cells studied in this individual. Percentage and MFI are
shown in left and right panels, respectively. The correspondingmeasurements of the total tetramer positive population were used to calculate mean and
95% confidence intervals shown (solid horizontal lines). Also shown is the range of values defined by the mean +/2 3*SD (dotted horizontal lines). PD-1
percentage and MFI values outside the more stringent ranges are considered significantly different from the total tetramer positive population. The
table inset shows the percentages of the V-beta subsets of A2-BRLF-1 CD8+ T cells in AIM and convalescence for this individual.
doi:10.1371/journal.pone.0012926.g008
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frequency of V-beta usage (i.e. immunodominance), it remains
possible that avidity relates to PD-1 expression.
Previous studies have emphasized a relationship between high
levels of antigenic stimulation and high PD-1 expression levels on
virus-specific CD8+ T cells in chronic viral infections. In a murine
model of LCMV infection, graded levels of PD-1 expression on
virus-specific CD8+ T cells correlated with viral clearance rates at
day 30 after infection [38]. The highest levels of PD-1 expression
were found on exhausted virus-specific CD8+ T cells in animals
with chronically elevated LCMV titers. Whereas PD-1 expression
on virus-specific CD8+ T cells in untreated HIV-1 (or SIV in
animal models of AIDS) infection is high and is directly related to
viral replication [8,13,34], PD-1 expression on CMV-specific
CD8+ T cells is reportedly lower; presumably due to intermittent
or lower levels of viral antigen expression. Relatively high levels of
PD-1 expression on EBV-specific CD8+ T cells from chronically
infected individuals have been reported by a number of groups
[8,13]. Most studies that have compared PD-1 expression on EBV
vs. HIV or CMV specific CD8+ T cells have focused on A2-
BMLF-1 CD8+ T cells [8,13]. Our results are in agreement with
these previous reports, however, we have also demonstrated
consistent and significant differences in PD-1 expression among
different epitope specific CD8+ T cell subsets.
The concept that circulating virus-specific CD8+ T cells with
different epitope specificities may display consistent differences in
PD-1 expression has precedent in the literature. Using a broad
panel of pMHCI tetramers to characterize HIV-specific CD8+ T
cell responses in infected individuals, Day and colleagues observed
lower levels of PD-1 expression on certain epitope-specific CD8+
T cells among a majority that expressed PD-1 at high levels [8]. A
dramatic difference in PD-1 expression on virus-specific CD8+ T
cells with different epitope specificities has also been reported in an
individual with resolved HCV infection [10]. Our data demon-
strated consistent differences in PD-1 expression on A2-BMLF-1
and A2-BRLF-1 CD8+ T cells over the course of infection from
AIM to convalescence, and between different individuals. This
suggests a mechanism that relates to differences in TCR signaling
that are shared by HLA-A*0201 positive individuals responding to
these epitopes. Possible mechanisms include: 1) differences in the
stability of the peptide/MHC-1 association, or 2) a common
limitation on TCR signaling (perhaps defined by the avidity of the
TCR for the pMHCI complex). Our data show that exposure of
epitope-specific CD8+ T cells to high (presumably saturating)
peptide concentrations result in different degrees of PD-1
upregulation, consistent with PD-1 expression ex vivo. This is
unlikely to be a function of limiting concentrations of pMHCI
complexes on the antigen presenting cells. MHC-peptide binding
algorithms actually predict that the A2-BRLF-1 epitope has a
longer half-life of dissociation from HLA-A*0201 than the A2-
BMLF-1 epitope. If antigen presentation were the most critical
factor, the less stable pMHCI complex might be expected to be
associated with lower PD-1 expression. Therefore, it is more likely
that there is a determinant of PD-1 upregulation specific to the
cells responding to these particular epitopes. The observation that
PD-1 expression may vary significantly in different V-beta subsets
that recognize the same epitope suggests that V-beta usage itself
may influence PD-1 expression. Further studies are necessary to
better define determinants of PD-1 expression on virus-specific
CD8+ T cells and their functional consequences.
Given our current understanding of EBV replication, it is likely
that different EBV lytic antigens are presented to CD8+ T cells in
a similar microenvironment, and in a similar time frame. The
differences in PD-1 expression on A2-BMLF-1 and A2-BRLF-1
CD8+ T cells, despite highly similar differentiation phenotypes,
suggests a dissociation between signaling pathways that determine
differentiation states and PD-1 expression. We have examined the
relationship between PD-1 expression and CD127 in detail
because a recent report indicates that CD127 expression is tightly
linked with proliferative capacity, a function that is lost early as
PD-1 is upregulated [7]. Furthermore, upregulation of both PD-1
and CD127 has been reported to precede disappearance of an
EBV-specific CD8+ T cell from the circulation [31]. We found
that few CD8+ T cells expressing high levels of PD-1 also
expressed CD127 in AIM, but this relationship was not exclusive;
higher frequencies of CD127+, PD-1+ cells were seen in
convalescence. As reported by Salisch et al, PD-1 expression on
virus-specific CD8+ T cells is a sensitive indicator of lentiviral
replication [16]. Kasprowicz et al have also suggested that PD-1
staining is compatible with it being an activation marker [10]. Our
analyses are consistent with these interpretations. While PD-1
levels correlated with the contraction of CD8+ T cells, we did not
find a simple association between higher PD-1 levels on EBV-
specific CD8+ T cells and the degree of contraction from AIM to
convalescence. Within a particular epitope specific subset (e.g. A2-
BRLF-1 CD8+ T cells), there can be a significant correlation,
however between subsets, similar levels of contraction occur with
significantly different PD-1 expression (Figure 4B, right panel).
This suggests that PD-1 may be necessary, but not sufficient in this
process.
Sauce et al [31] have described transient increases in PD-1
expression on epitope-specific CD8+ T cells that are associated
with an ‘‘accelerated’’ expression of CD127 and subsequent
disappearance of that epitope-specific response from the circula-
tion. Consistent differences in PD-1 staining intensity were not
reported in their analysis of A2-BMLF-1 (labeled ‘‘GLC’’) than
A2-BRLF-1 (labeled ‘‘YVL’’) CD8+ T cells in acutely infected
individuals at all time points to convalescence. However, careful
inspection of the data presented actually demonstrates higher PD-
1 expression on A2-BMLF-1 than A2-BRLF-1 CD8+ T cells in
three of four individuals at multiple time points, and in the fourth
subject during acute infection. Differences in PD-1 expression may
have been less evident due to the binding characteristics of the
anti-PD-1 antibody used. Indeed, we had collected additional
earlier data using a different anti-PD-1 antibody that failed to
clearly distinguish positive and negative populations, yet still
demonstrated these differences in PD-1 expression at all time
points (data not shown). Using another antibody (Medarex), we
observed PD-1 expression profiles with clearly defined bimodal
distributions (data reported here in Figures 3A, 5, 7A, 8A). The
ability to distinguish differences in intensity of PD-1 expression,
particularly PD-1high expression, has been previously shown to be
critical for describing meaningful biological differences.
The functional impact of PD-1 upregulation on EBV-specific
CD8+ T cells during AIM is unclear. We found virtually no
proliferation to peptide stimulation during AIM, and no
enhancement of proliferation in the presence of antibody blocking
the PD-1/PD-L1 interaction. While PD-1 upregulation may
contribute to loss of responsiveness, it certainly cannot explain it
in entirety. Our findings are consistent with other reports that PD-
1 expression alone does not explain loss of proliferative capacity or
sensitivity to apoptosis [12,39]. In convalescence, the inhibitory
activity associated with PD-1 is more evident; enhanced
proliferative responses are observed in the presence of anti-PD-
L1. Our observations thus highlight the complexities of PD-1
expression and its functional correlates; in some settings (e.g.
chronic LCMV infection in mice), its expression is consistent with
cellular exhaustion [6], while in others (e.g. acute hepatitis C
infection), it appears primarily to be a marker of activation [10].
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Blackburn et al have shown that there may be multiple inhibitory
molecules that contribute to an ‘‘exhausted’’ phenotype [38], and
that PD-1/PD-L1 blockade primarily rescues proliferation in less
terminally differentiated cells [39]. We have now shown that these
complexities must be viewed through a lens that accounts not only
for antigen expression, but also epitope specificity and V-beta
usage.
In aggregate, studies indicate that PD-1 expression and
signaling play an important role in limiting pathogenic conse-
quences of chronic virus infection. Efforts are underway to
determine if disrupting the interaction of PD-1 with its ligands will
have a beneficial effect in chronic viral infections in which cellular
immunity fails to provide control. We have shown that PD-1
expression is induced by antigenic stimulation, but is dependent in
part on intrinsic properties of the responding cell. Consistent
differences, and significant variability in PD-1 expression observed
in two lytic epitope specific CD8+ T cell subsets, and
subpopulations defined by V-beta usage point to properties that
are likely linked to TCR signaling, TCR avidity and recruitment
of molecules involved in signal transduction. Properties of TCR-
pMHCI interactions that influence expression of PD-1 are likely to
inform the future designs of vaccines and immunotherapeutics.
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